Clinical trial · Observational
A Study to Explore Clinical Characteristics and Prognoses of N2 Patients With Non-small Cell Lung Cancer
A Multi-centre Real-world Non-interventional Observational Study to Explore Clinical Characteristics of Lymph Skip Metastases and Prognoses of N2 Patients With Non-small Cell Lung Cancer
NCT03429192CI-TRIAL-00033012completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
A study to compare patient survivals in the N2 patients with non-small cell lung cancer in the subgroups of lymph skip metastases and non-skip metastases
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non-small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Surgery | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- N2 non-small cell lung cancer
- description
- Chinese patients with N2 non-small cell lung cancer
- interventionNames
- Procedure: Surgery
Primary outcomes (1)
- measure
- Difference in overall survival (OS)
- timeFrame
- 2014 - 2017
- description
- OS difference in the subgroups of N2 patients with lymph skip metastases and non-skip metastases
Secondary outcomes (1)
- measure
- Percentage of N2 patients with lymph skip metastases
- timeFrame
- 2014 - 2017
- description
- Percentage of N2 patients with lymph skip metastases
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with surgeries from 2014 to 2017; * Pathologically diagnosed patients with non-small cell lung cancer; * Age \> 18 years old; * Patients with chest surgeries before hospitalization; * Patients with N2 lymph nodes (+) after surgeries who received lymphadenectomy (Group 10 and 11 lymph nodes); Exclusion Criteria: \- Patients with radiotherapies, chemotherapies and biological therapies for tumors
References
Publications (1)
- DERIVEDLi X, Li X, Fu X, Liu L, Liu Y, Zhao H, Li Y, Hu J, Xu L, Liu D, Yang H, Zhang X. Survival benefit of skip metastases in surgically resected N2 non-small cell lung cancer: A multicenter observational study of a large cohort of the Chinese patients. Eur J Surg Oncol. 2020 Oct;46(10 Pt A):1874-1881. doi: 10.1016/j.ejso.2019.12.015. Epub 2019 Dec 18. PMID 31902592